Naltrexone vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.222 | 0.132 | 0.349 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.304 | 0.199 | 0.433 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.0813 | -0.239 | 0.0833 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.732 | 0.387 | 1.38 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.655 | 0.278 | 1.55 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with a serious adverse event on Naltrexone than on Placebo | 12.3 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Naltrexone | Randomized patients received 4.5 mg low dose naltrexone (LDN) to be taken every night before bed. | 12 | 54 | EG000 | ClinicalTrials.gov |
| Group 2 | Placebo | Randomized patients received placebo to be taken every night before bed. | 17 | 56 | EG001 | ClinicalTrials.gov |
Harm 2
| Field | Value | Source |
|---|---|---|
| What it counts | Total, serious adverse events | ClinicalTrials.gov |
| Time frame | 24 weeks | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Low Dose Naltrexone for Glioma Patients | ClinicalTrials.gov |
| NCT number | NCT01303835 | ClinicalTrials.gov |
| Phases | PHASE2 | ClinicalTrials.gov |
| Conditions | Malignant Glioma | ClinicalTrials.gov |
| Interventions | LDN, Placebo | ClinicalTrials.gov |
| Lead sponsor | Katy Peters | ClinicalTrials.gov |
| Results first posted | 2015-06-26 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT01303835?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.